Alnylam Pharmaceuticals
ALNY
#564
Rank
A$61.77 B
Marketcap
A$467.60
Share price
-0.93%
Change (1 day)
5.96%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of February 2026 (TTM): 13.6

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 186. At the end of 2025 the company had a P/S ratio of 18.2.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2025

PS ratio at the end of each year

Year P/S ratio Change
202518.233.52%
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Novartis
NVS
5.35-60.59%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
2.45-81.97%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
5.81-57.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.7969-94.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
1.53-88.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
2.43-82.06%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
11.1-18.34%๐Ÿ‡บ๐Ÿ‡ธ USA